Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Péptidos de mejillón contra herpesvirus

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20161021004
Publicado:
01/12/2016
Caducidad:
01/12/2017
Resumen:
Un equipo de investigación español ha obtenido péptidos modificados de miticina de mejillón (Mytilus galloprovincialis) para el tratamiento de infecciones de herpesvirus en animales y humanos. Los investigadores han descubierto que la miticina C es capaz de reducir considerablemente la carga viral de herpesvirus de ostreidos, el patógeno responsable de la mortalidad masiva de la Crassostrea gigas cultivada en Francia y otros países del mundo. Además cuando una secuencia del péptido que permite la entrada en las células se une a la miticina C, este péptido modificado también es capaz de reducir considerablemente la carga viral en herpesvirus humanos. El equipo de investigación busca compañías biotecnológicas, farmacéuticas o veterinarias interesadas en antimicrobianos para establecer acuerdos de investigación y licencia.

Details

Tittle:
Mussel peptides against herpesvirus
Summary:
A research research group from CSIC has obtained modified peptides from mussel (Mytilus galloprovincialis) myticin for the treatment of herpesvirus infections in animals and humans. We are looking for biotechnological, pharmaceutical or veterinary companies interested in antimicrobials for research cooperation and licensing of these products.
Description:
Diseases caused by herpesvirus affect to a wide range of species such as mammals, birds, fish, amphibian and molluscs. Concerning humans, herpes simplex virus type 1 (HSV-1, or oral herpes virus) and type 2 (HSV-2, or genital herpes virus) are possibly amongst the most serious. In other animals (dogs, cats, bovine and porcine) several herpesvirus variants have significant economical impact. Currently, there are not vaccines against these viruses only some medicines such as Acyclovir, Penciclovir Famciclovir and analogs. All of them inhibit viral replication and are able to control the infection but they can not prevent its recurrence. Moreover, their administration is associated with adverse effects, sometimes serious.
The researchers have found that Myticin C, already know in the bibliography, is able to significativelly reduce the viral load of oyster herpesvirus, the pathogen responsable of the mass mortalities of the cultured Crassostrea gigas in France and other countries in the world. Moreover, when a peptide sequence allowing the entrance in the cells is binded to the Myticin C, this modified peptide is also able to significativelly reduce the viral load in human herpes viruses. This opens the door to new pharmaceutical and veterinary compositions for the treatment of herpesvirus infections in many human or animal species.
Advantages and Innovations:
· Wide range of herpesvirus potentially targets of this modified peptide: herpes simplex virus1, herpes simplex virus 2, herpes zoster, Epstein-Barr, cytomegalovirus, roseolovirus or herpesvirus associated to the Kaposi´s sarcoma
· Easy administration and adaptable to different species.
· The conducted assays reveal a high selective index.
Stage of Development:
Field tested/evaluated
IPs:
Patent(s) applied for but not yet granted

Partner sought

Type and Role of Partner Sought:
Biotech, pharma company dealing with proteins as antimicrobians

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06002004 Ingeniería de proteínas